Holen Sie sich die Stockscreener-App
31.83
4.57%
1.39
Handel nachbörslich:
31.25
-0.58
-1.82%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$30.44
Offen:
$30.67
24-Stunden-Volumen:
2.95M
Relative Volume:
1.54
Marktkapitalisierung:
$2.94B
Einnahmen:
$490.73M
Nettoeinkommen (Verlust:
$-50.26M
KGV:
-52.79
EPS:
-0.603
Netto-Cashflow:
$-20.37M
1W Leistung:
+15.08%
1M Leistung:
+16.85%
6M Leistung:
+21.81%
1J Leistung:
+112.34%
1-Tages-Spanne:
$30.67
$33.78
1-Wochen-Bereich:
$27.96
$33.78
52-Wochen-Spanne:
$12.91
$42.13
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
31.83 | 2.81B | 490.73M | -50.26M | -20.37M | -0.603 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Therapeutics (NASDAQ:TVTX) Shares Up 7.7%Still a Buy? - MarketBeat
Travere Therapeutics (TVTX) Stock Rises Over 9% in Market Session - gurufocus.com
TD Cowen Maintains Travere Therapeutics (TVTX) Buy Recommendation - MSN
Buyback Watch: Is Travere Therapeutics Inc trading at a discount2026 Macro Moves & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Palisades Investment Partners LLC Invests $5.26 Million in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 60,000 Shares - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $300,000.00 in Stock - MarketBeat
Travere therapeutics CEO Dube sells $1.8m in TVTX stock By Investing.com - Investing.com Canada
Travere therapeutics chief legal officer sells $300k in TVTX stock - Investing.com
Travere therapeutics chief legal officer sells $300k in TVTX stock By Investing.com - Investing.com Australia
Travere Therapeutics (TVTX) CEO sells 60K shares after option exercise - Stock Titan
Travere (NASDAQ: TVTX) CLO exercises options, pre-planned sale of 10K shares - Stock Titan
Travere Awaits FDA FILSPARI Ruling As Valuation Gap Draws Attention - Yahoo Finance
(TVTX) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
TVTX (NASDAQ: TVTX) files Form 144 for 60,000-share sale - Stock Titan
Elizabeth Reed registers sale of 10,000 TVTX shares (TVTX) via option exercise - Stock Titan
Hennion & Walsh Asset Management Inc. Increases Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
A Look At Travere Therapeutics (TVTX) Valuation After Recent Share Price Pullback - simplywall.st
Tudor Investment Corp Cuts Stake in Travere Therapeutics - National Today
Tudor Investment Corp ET AL Cuts Stake in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere, CSL gets standard EU approval for kidney disorder treatment - MSN
JPMorgan Chase Cuts Travere Therapeutics Price Target - National Today
Vanguard disaggregates holdings; reports 0 TVTX shares (Vanguard) - Stock Titan
Travere Therapeutics, Inc. $TVTX Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
J.P. Morgan Gives a Buy Rating to Travere Therapeutics (TVTX) - The Globe and Mail
Aug Spikes: Should value investors consider Travere Therapeutics Inc2026 Price Swings & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Travere Therapeutics price target lowered to $41 from $44 at JPMorgan - TipRanks
Earnings Risk: Is Cayson Acquisition Corp Equity Right stock a falling knife or bargain buy2026 Volatility Report & High Accuracy Swing Trade Signals - baoquankhu1.vn
FOMO Trade: Is Snail Inc forming bullish engulfing patternsMarket Trend Review & Weekly Top Gainers Trade List - baoquankhu1.vn
JPMorgan Chase & Co. Has Lowered Expectations for Travere Therapeutics (NASDAQ:TVTX) Stock Price - MarketBeat
JP Morgan Lowers Price Target for TVTX to $41.00, Maintains Over - GuruFocus
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Travere Therapeutics (TVTX) Gains Attention with Potential FDA A - GuruFocus
Citi opens ‘upside 90-day catalyst watch’ on Travere Therapeutics - TipRanks
Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts - MSN
A Look At Travere Therapeutics (TVTX) Valuation After Recent Share Price Volatility - simplywall.st
Travere Therapeutics (TVTX) reports 144% annual growth in Filspari sales for 2025 - MSN
Responsive Playbooks and the TVTX Inflection - Stock Traders Daily
Travere Therapeutics, Inc. (TVTX) positioned for long-term growth in rare disease market - MSN
Highs Report: Can Travere Therapeutics Inc be recession proofShare Buyback & Growth Focused Investment Plans - baoquankhu1.vn
Is Travere Therapeutics (TVTX) Pricing Signal An Opportunity After Recent Share Price Pullback? - simplywall.st
Travere Therapeutics Inc SEC Filings - Stock Titan
TVTX Earnings History & Surprises | EPS & Revenue Results | TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) - ChartMill
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $280,900.00 in Stock - MarketBeat
Travere Therapeutics (TVTX) CLO exercises options and sells 10K shares - Stock Titan
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs - MSN
Cinctive Capital Management LP Makes New $2.26 Million Investment in Travere Therapeutics, Inc. $TVTX - MarketBeat
Earnings Recap: Is Travere Therapeutics Inc stock heavily shorted2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
[144] Travere Therapeutics, Inc. SEC Filing - Stock Titan
166,000 Shares in Travere Therapeutics, Inc. $TVTX Purchased by Apis Capital Advisors LLC - MarketBeat
How Investors Are Reacting To Travere Therapeutics (TVTX) FILSPARI Momentum And Mirum Milestone Windfall - Sahm
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Travere Therapeutics Inc-Aktie (TVTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Apr 01 '26 |
Sale |
30.93 |
60,000 |
1,855,839 |
432,886 |
| REED ELIZABETH E | Chief Legal Officer and GC |
Apr 01 '26 |
Option Exercise |
15.46 |
10,000 |
154,600 |
115,211 |
| REED ELIZABETH E | Chief Legal Officer and GC |
Apr 01 '26 |
Sale |
30.00 |
10,000 |
300,000 |
105,211 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):